Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report.

Abstract

Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported. We report a patient with VGPA stage IIA responding to neoadjuvant chemotherapy with docetaxel (60 mg/m2 as an intravenous infusion) and cisplatin (70 mg/m2 as an intra-arterial infusion). At 3 weeks after completing one course of this regimen, the tumor size was reduced from 5.3 x 4.0 cm to 2.0 x 2.0 cm (81.1% reduction), revealed by computed tomography. Accordingly, the patient underwent radical hysterectomy, and there have been no signs of recurrence. Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.

• Authors: N Nagai, E Hirata, T Kusuda, K Mukai, K Arihiro, K Ohama
• Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) 2005 Nov-Dec Vol. 15 Issue 6 Pg. 1187-90 ISSN: 1048-891X [Print] England
• PMID: 16343210 (Publication Type: Case Reports, Journal Article)

Chemical References

• Taxoids
• Docetaxel
• Cisplatin

Topics

• Adenocarcinoma, Papillary (drug therapy, pathology, surgery)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Cisplatin (administration & dosage)
• Docetaxel
• Female
• Humans
• Hysterectomy
• Middle Aged
• Neoadjuvant Therapy
• Taxoids (administration & dosage)
• Treatment Outcome
• Uterine Cervical Neoplasms (drug therapy, pathology, surgery)